Tandem Mobi Is FDA Cleared for Tubeless Wear. The 7 Days Applies to the Infusion Set.
The FDA cleared a new cartridge and infusion set that let the Tandem Mobi be worn without tubing. Here is what was cleared, what the seven days covers, and when it is expected.
Tandem Mobi: cleared for tubeless wear
On November 12, 2026, the FDA cleared a new cartridge and infusion set that let the Tandem Mobi insulin pump be worn without tubing. It is a clearance, not a launch: Tandem plans U.S. availability in the first half of 2027.
What was cleared
- A tubeless cartridge and infusion set for the current Mobi pump (Tandem press release and SEC filing).
- Tandem says customers with an in-warranty Mobi will not need a new pump.
- Infusion set: cleared for up to 7 days of wear. Cartridge: cleared for 3 days of use.
- Mobi stays cleared for tubed wear, with the same Control-IQ+ technology.
What the announcement does not tell you
- The price. None has been announced.
- Clinical study results for tubeless wear. The release reports none.
- Which CGMs are involved. The release names no brands.
For people who use or are considering a pump
- Cleared is not the same as available. Tandem’s stated plan is the first half of 2027, and the company notes that timing can change.
- Tubeless supplies will be sold only through pharmacies, for customers with pharmacy benefits. Tandem estimates that coverage reaches about 50% of insured U.S. lives.
- Decisions about pumps and wear time belong with each person and their care team.
Tandem Diabetes Care is a sponsor of the Juicebox Podcast. Tandem did not sponsor this post.
Educational only. Not medical advice. Talk with your doctor before making any changes to your care. juiceboxpodcast.com
On November 12, 2026, Tandem Diabetes Care received FDA 510(k) clearance for a new cartridge and infusion set that convert the Tandem Mobi insulin pump into a tubeless device, according to the company’s press release and its filing with the SEC. The pump is now cleared to be worn with tubing or without it.
Tandem’s headline calls Mobi the “world’s first and only” tubeless automated insulin delivery system with up to seven days of wear. That claim is the company’s, and it rests on a footnote. The seven days applies to the infusion set. The cartridge is cleared for three.
The video below covers the announcement in 80 seconds. The rest of this post lays out the details and what has not been announced.
Felt film from the Juicebox Podcast YouTube channel. Watch on YouTube.
What the FDA cleared
The clearance is for supplies, not a new pump. A tubeless cartridge and a tubeless infusion set attach to the Mobi that is already on the market. Tandem says existing Mobi pumps are compatible, and that customers whose pump is still in warranty will not need a new one.
Mobi also keeps its tubed option. Tandem describes it as the only pump cleared for both, which is a company claim. The automation is unchanged: the pump runs the same Control-IQ+ technology either way.
A 510(k) clearance means the FDA has cleared the device for sale. The press release does not report clinical study results for the tubeless configuration, and this post does not claim any.
What the 7 days covers
The footnote in Tandem’s release separates two parts. The tubeless infusion set is cleared for up to seven days of wear. The cartridge, which holds the insulin, is cleared for three days of use. The Mobi cartridge holds 200 units.
An editorial read of that footnote: the seven-day figure describes how long the site is cleared to stay on the body, not how long one fill of insulin is cleared to be used. Tandem’s release frames the benefit as less frequent site changes, which matches the footnote.
When it is expected, and where
Tandem says a full U.S. commercial launch of the tubeless cartridge and infusion set is planned for the first half of 2027. The company says it will contact eligible customers when the supplies are available.
The tubeless supplies will be sold only through pharmacies, for customers with pharmacy benefits. Tandem estimates that pharmacy coverage for Mobi reaches about 50% of insured U.S. lives and says it expects that to grow. The release also notes that the timeline depends on the company’s ability to scale and support the product, so the dates are plans, not commitments.
What has not been announced
Several things a person would want to know are not in the release.
The price
No price for the tubeless cartridge or infusion set has been announced. The only cost detail in the release is that in-warranty Mobi owners will not need a new pump.
Clinical results for tubeless wear
The release reports no study results for the tubeless configuration.
Which CGMs it works with
The release refers to interoperable continuous glucose monitors and names no brands.
How it attaches to the body
Tandem’s product images are captioned as shown without the necessary adhesive. The release does not describe the adhesive or where on the body the pump is cleared to be worn.
What this means for people who use or are considering a pump
For someone already using a Mobi, the announcement describes a future supply option for the pump they have, if their insurance includes pharmacy coverage for it. For everyone else, it is a cleared product that cannot be obtained yet. Cleared and available are different things, and the gap here is measured in months.
Tandem Diabetes Care is a sponsor of the Juicebox Podcast. Tandem did not sponsor this post or the video in it. Which pump to use, and how long to wear a site, are decisions for each person and their care team. Talk with your doctor before making any changes to your care.
Press release. Tandem Diabetes Care. Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear. Business Wire via Tandem investor relations, November 13, 2026.
SEC filing. Tandem Diabetes Care. Form 8-K, event dated November 12, 2026. SEC EDGAR, filed November 13, 2026.
Product page. Tandem Diabetes Care. Tandem Mobi Tubeless. tandemdiabetes.com, viewed November 15, 2026.
How to read this. The clearance date and the seven-day and three-day figures appear in a filing made to the SEC. The launch timing and the pharmacy coverage estimate are the company’s forward-looking statements. The first-and-only wording and the claim that Mobi is the only pump cleared for both wear options are Tandem’s descriptions. They were not independently checked against every other pump. The tubeless supplies are cleared but not yet on sale.
This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any device or medication. Talk with your doctor before making any changes to your care.
Listen to the Juicebox Podcast
Conversations about diabetes, five days a week, since 2015.
Read the full disclaimer